hydronidone
Phase 1- Indications
- Hepatitis B associated fibrosis, Non-alcoholic steatohepatitis
Company intelligence / Profile preview
Gyre Therapeutics, Inc.
South San Francisco, California, United Statesir.catalystbiosciences.com ↗
- Ownership
- Public · CBIO
- Development stage
- Phase 1
01
Overview
The company has a Phase 3 drug F351 (hydronidone) for the treatment of HBV associated liver fibrosis in China and plans to initiate Phase 2 studies in NASH fibrosis. Previously developed MarzAA (marzeptacog alpha activated) and DalcA (dalcinonacog alpha) for rare bleeding disorders, which were sold to GC Biopharma.
- Therapeutic areas
- GastroenterologyOphthalmologyImmunologyHematologyRare DiseasesInfectious Diseases
- Modalities
- Small moleculesRecombinant proteinsAAV-based gene therapyEngineered human proteases
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Gyre Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gyre Therapeutics, Inc..